Arch Biopartners Stock Quote ARCH - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

1.89

Bid

1.88

Ask

1.90

Volume

3,483

1.89 Day's Range 1.91

0.97 52 Week Range 2.56

Market Cap

118.31M

Previous Close

1.90

Open

1.91

Last Trade

1.89

Last Trade Time

10:12:51

Financial Volume

VWAP

Average Volume (3m)

13,177

Shares Outstanding

62,598,000

Dividend Yield

PE Ratio

-35.78

Earnings Per Share (EPS)

-0.05

Revenue

1.98M

Net Profit

-3.33M

Sector

Coml Physical, Biologcl Resh

Industry

Advertising Agencies

Website

archbiopartners.com

Headquarters

Toronto, Ontario, Can

Founded

2010

Arch Biopartners Inc is listed in the Coml Physical, Biologcl Resh sector of the TSX Venture Exchange with ticker ARCH. The last closing price for Arch Biopartners was $1.90. Over the last year, Arch Biopartners shares have traded in a share price range of $ 0.97 to $ 2.56.

Arch Biopartners currently has 62,598,000 shares outstanding. The market capitalization of Arch Biopartners is $118.94 million. Arch Biopartners has a price to earnings ratio (PE ratio) of -35.78.

FeaturedCBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024

Closes Units for Debt Settlement

TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has closed a transaction that...

Units for Debt Settlement

TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a transaction to...

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Alberta Health Services (AHS) has approved...

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its...

Arch Biopartners Closes Non-Brokered Private Placement

TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has closed the non-brokered private placement...

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, July 29, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement...

Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product

TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that Dalton Pharma Services (Dalton) has completed the...

Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary’s Conjoint Health...

St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.09	5	1.8	2	1.77	4952	1.85347334	CS
4	0.39	26	1.5	2	1.4	10965	1.65086533	CS
12	0.25	15.243902439	1.64	2	1.36	13177	1.5465264	CS
26	-0.49	-20.5882352941	2.38	2.41	1.36	17412	1.75010211	CS
52	0.79	71.8181818182	1.1	2.56	0.97	20052	1.68764595	CS
156	-0.08	-4.06091370558	1.97	5.3	0.97	23900	2.51574829	CS
260	0.92	94.8453608247	0.97	5.3	0.74	26939	1.96948567	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MGIMagnum Goldcorp Inc	$ 0.025 (150.00%)	916k
INFDInfield Minerals Corp	$ 0.03 (50.00%)	399.25k
LMSLatin Metals Inc	$ 0.11 (46.67%)	21k
QPTQuest PharmaTech Inc	$ 0.035 (40.00%)	60k
PINNPinnacle Silver and Gold Corp	$ 0.04 (33.33%)	294.67k
ODX.HOdyssey Resources Limited	$ 0.015 (-50.00%)	2k
ETUE2gold Inc	$ 0.005 (-50.00%)	5k
HMANHuntsman Exploration Inc	$ 0.03 (-40.00%)	1.5k
JECJura Energy Corporation	$ 0.04 (-38.46%)	29k
ENTGEntourage Health Corp	$ 0.01 (-33.33%)	12.6k
CLCOCulico Metals Inc	$ 0.13 (30.00%)	1.89M
PERUChakana Copper Corp	$ 0.025 (-28.57%)	1.85M
DMDataMetrex AI Limited	$ 0.005 (0.00%)	1.65M
MGIMagnum Goldcorp Inc	$ 0.025 (150.00%)	916k
REVORevolugroup Canada Inc	$ 0.03 (-14.29%)	592.14k